Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Search results
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
In January 23-year-old Jake Ternent became the first person with an inherited sight loss condition to be treated in the UK with Luxturna (voretigene neparvovec) for Leber congenital amaurosis (LCA).
TPT and Sight Loss Councils: Cut it back campaign
In 2014 we funded an exciting new collaborative project. The UK Inherited Retinal Dystrophy Consortium (UKIRDC) Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs).
Giving a regular monthly or quarterly donation of any amount is a wonderful way to help Retina UK support the inherited sight loss community.
February is Retinitis Pigmentosa Awareness Month and we'd love you to get involved to enhance the work of Retina UK, as we continue to support those who are living with retinitis pigmentosa and other inherited sight loss conditions.
Funding from Retina UK has allowed to team to explore the viability of gene therapy as a treatment for RP and related conditions, and build a pipeline of clinical trials.
Thursday 6 February, 7.00pm - 8.30pm - via Zoom - Are you aged 18 to 30 and living with an inherited retinal dystrophy? Then come and join us for our first online social of 2025.